Citation Impact
Citing Papers
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
2019 Science
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
1999 Standout
The FGF family: biology, pathophysiology and therapy
2009 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Chemotherapy for malignant gliomas
1988
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
2004 Standout
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study
1990 StandoutNobel
Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America
2002
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Metabolism and reactions of quinoid anticancer agents
1987
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
1990 Standout
Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
1989
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder
1996
Paclitaxel (Taxol)
1995 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
2004
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
1988
Anthrazykline in der Krebstherapie
1997 Standout
Etoposide in the management of metastatic breast cancer
1991
Molecular mechanisms of quinone cytotoxicity
1991 Standout
Chemotherapy in malignant mesothelioma: a review
1991
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
1995
Toxicity profile of dexrazoxane (zinecardR, icrf-187, adr-529, nsc-169780), a modulator of doxorubicin cardiotoxicity
1991
Tolerance of normal tissue to therapeutic irradiation
1991 Standout
A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens
1988
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
1995
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.
1993 Standout
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
1991 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Chemotherapy in malignant pleural mesothelioma. A review.
1996
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
1992 Standout
Management of malignant pleural effusions
2001 Standout
Current status of etoposide in the management of small cell lung cancer
1991
Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282
1999
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
1998
A Review of Chemotherapy Trials for Malignant Mesothelioma
1998
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
1996 Standout
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Paclitaxel and its formulations
2002 Standout
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
1989
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer.
1985
Dose response evaluation of adriamycin in human neoplasia
1977
A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II
1979
Chemotherapy of brain metastases: Current status
1984
Taxol: the first of the taxanes, an important new class of antitumor agents.
1992
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Phase II studies with carboplatin in non-small cell lung cancer.
1990
Chemotherapy for advanced gastric cancer
2017 Standout
Breast Cancer Treatment
2019 Standout
Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.
1986
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
2001
Drug Treatment of Breast Cancer
1978
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
2004 Standout
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.
1987
The importance of dose intensity in chemotherapy of metastatic breast cancer.
1984 Standout
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
2000
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors
1980
Adriamycin cardiotoxicity in stage IV breast cancer: Possible enhancement with prior left chest radiation therapy
1979
Role of Quinones in Toxicology
2000 Standout
Oxygen Radicals and Human Disease
1987 Standout
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Metabolic reprogramming and cancer progression
2020 StandoutScience
Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomized controlled study
1994
Basic principles in the use of adjuvant therapy.
1990
The Chemistry of Neutron Capture Therapy
1998 Standout
New agents in non-small cell lung cancer
1984
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Pleural mesothelioma: combined modality treatments
2002
Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma.
1983 StandoutNobel
Chemotherapy Alone or Chemotherapy with Chest Radiation Therapy in Limited Stage Small Cell Lung Cancer
1987
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
VP-16-213 (etoposide): The mandrake root from Issyk-Kul
1982
The Anthracycline Antineoplastic Drugs
1981 Standout
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
2001
The Treatment of Soft-tissue Sarcomas of the Extremities
1982 Standout
Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report.
1984
Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival
1989
Cisplatin
1984 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of Eagan Rt being referenced
VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
1978
Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.
1974
Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
1977
cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.
1978
Phase II study on DON in patients with previously treated advanced lung cancer.
1982
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.
1981
Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
1976
Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
1983
Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
1977
Complications of treatment of small cell carcinoma of the lung.
1983
ICRF-159 versus polychemotherapy in non-small cell lung cancer.
1976
Phase II evaluation of AMSA in patients with metastatic lung cancer.
1980
Phase I study of diaziquone.
1984
Phase II studies of polychemotherapy regimens in small cell lung cancer.
1977
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
1982
Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
1982
VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
1976
Phase II trial of diaziquone in malignant mesothelioma.
1986
A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer.
1981